Analysis of Obesity GLP-1 Market by Key Country The obesity GLP-1 market is growing rapidly across major economies, with China and the United States both recording 25.4% CAGR through 2035, driven by large treatment-eligible populations and expanding access frameworks
Voraussetzung sind ein spezialisiertes multidisziplinres Setting, engmaschige Verlaufskontrollen, definierte Abbruchkriterien sowie eine dokumentierte Aufklrung, insbesondere bei Off-Label-Anwendung
Subject demographics (for example: age, sex, self-identified race), lab values (for example: HbA1c, BMI, liver enzymes), and some medication information (GLP-1 M, other drugs used to treat T2D, and NSAIDs) and presence or absence of diabetes-associated complications (for example: chronic kidney disease, cardiovascular disease) were extracted as prediction features
Tassorelli, C
Because I dont consume alcohol